^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | magrolimab (GS-4721) (CD47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
Published date:
09/21/2022
Excerpt:
Magrolimab+azacitidine was well tolerated, with promising effi cacy in patients with untreated HR MDS, including those with TP53-mutated and –wild-type disease.
Secondary therapy:
azacitidine
Trial ID:
